Ovarian Cysts

Ovarian cysts are fluid-filled or partially fluid-filled structures arising from or within the ovary, encountered across all age groups from neonates to post-menopausal women. The majority are benign and resolve spontaneously, but a systematic approach to characterization — using ultrasound morphology, validated risk-stratification systems, and clinical context — is essential to distinguish functional from pathological lesions and to identify the minority requiring surgical evaluation for suspected malignancy.

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Etiology and Risk Factors
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Complications
  9. Prognosis
  10. Prevention
  11. Recent Research
  12. References

1. Overview

Ovarian cysts encompass a heterogeneous spectrum of lesions that require stratification into functional and pathological categories. Functional cysts (follicular and corpus luteum cysts) are physiological variants arising from normal ovarian cyclicity and represent the vast majority of cysts identified in premenopausal women. Pathological cysts include benign neoplasms (dermoid/mature teratoma, serous and mucinous cystadenoma, endometrioma) and malignant or borderline tumors requiring surgical evaluation and histopathological diagnosis.

Two principal risk-stratification frameworks guide clinical management:

2. Epidemiology

Ovarian cysts are among the most common incidental findings in gynecological practice and emergency imaging:

3. Pathophysiology

Functional Cysts

Follicular cysts arise when a dominant follicle fails to rupture at ovulation, continuing to enlarge beyond the normal 18–22 mm pre-ovulatory size, typically reaching 3–8 cm. Elevated LH levels (as in PCOS or exogenous gonadotropin stimulation) may precipitate multiple follicular cysts. Granulosa cell secretion of estradiol continues until spontaneous regression, which occurs in most cases within 1–3 menstrual cycles via atresia and follicular fluid resorption.

Corpus luteum cysts form when the corpus luteum fails to undergo normal luteolysis, persisting beyond 14 days and often reaching 3–10 cm. The corpus luteum is highly vascular (the most vascularized structure per unit volume in the body) and may hemorrhage internally, producing a hemorrhagic corpus luteum with complex echogenicity — often confused with endometrioma or ectopic pregnancy on ultrasound. Hemorrhagic corpus luteum cysts may rupture, causing hemoperitoneum, particularly in women on anticoagulation.

Endometrioma

Endometriomas ("chocolate cysts") arise from ectopic endometrial glands and stroma implanting on the ovarian cortex and invaginating into the ovarian parenchyma. Cyclical hemorrhage into the enclosed space produces hemosiderin-laden fluid with a characteristic "ground-glass" ultrasound appearance. The cyst wall lacks a true epithelial lining; the interface with the adjacent ovarian cortex is often indistinct, making enucleation technically challenging and predisposing to inadvertent excision of healthy ovarian follicles (reducing ovarian reserve). Endometriomas are estrogen-responsive and recur following surgical excision in up to 50% of cases within 5 years.

Dermoid Cysts (Mature Cystic Teratoma)

Arise from parthenogenetic development of a primordial germ cell, containing mature elements from two or three germ cell layers (ectoderm — skin, hair, sebaceous glands; mesoderm — fat, cartilage, bone; endoderm — thyroid tissue, bronchial epithelium). The sebaceous content appears echogenic with dense shadowing on ultrasound (Rokitansky nodule/dermoid plug). Malignant transformation to squamous cell carcinoma occurs in less than 2% of dermoid cysts, predominantly in post-menopausal women.

Serous and Mucinous Cystadenomas

Serous cystadenomas are lined by fallopian tube-type epithelium, typically unilocular or oligolocular with thin walls and anechoic contents. Serous borderline tumors (serous tumors of low malignant potential) may have micropapillary projections; distinction from low-grade serous carcinoma requires histological assessment. Mucinous cystadenomas may reach large dimensions (greater than 20 cm) and contain thick, mucinous fluid; they are multilocular with variable internal echogenicity. Pseudomyxoma peritonei — peritoneal dissemination of mucin-secreting epithelium — is a rare but serious complication, most commonly arising from appendiceal rather than primary ovarian mucinous tumors.

4. Etiology and Risk Factors

Factors Promoting Functional Cyst Formation

Risk Factors for Pathological Ovarian Cysts and Malignancy

5. Clinical Presentation

Asymptomatic Incidental Finding

The majority of ovarian cysts, particularly simple functional cysts under 5 cm, are detected incidentally on pelvic ultrasound performed for other indications (urinary tract symptoms, infertility workup, routine examination). Many resolve before the next menstrual cycle and require only follow-up imaging.

Pelvic Pain and Pressure

Enlarging cysts produce a sense of lower abdominal fullness, pressure, and unilateral pelvic aching. Pain may be cyclical with endometriomas (dysmenorrhea, deep dyspareunia) or constant with large neoplastic cysts compressing adjacent pelvic organs. Acute, severe unilateral pain should prompt immediate evaluation for torsion or rupture.

Menstrual Irregularity

Functional cysts may produce hormonal disturbance — follicular cysts secrete estrogen causing endometrial proliferation and delayed menstruation followed by irregular or heavy withdrawal bleeding; corpus luteum cysts maintain progesterone levels mimicking early pregnancy with amenorrhea. PCOM associated with PCOS produces oligomenorrhea and anovulatory cycles.

Ovarian Torsion

A gynecological emergency caused by partial or complete rotation of the ovary (with or without the fallopian tube) around the infundibulopelvic and utero-ovarian ligament axes, compromising vascular supply. Torsion occurs most commonly with cysts of 5–10 cm — large enough to tip the center of gravity but not so heavy as to prevent rotation. Classic presentation: acute onset severe unilateral lower abdominal pain (colicky then constant), nausea, vomiting, and low-grade fever. Physical examination reveals exquisite adnexal tenderness; an adnexal mass may be palpable. Torsion may be intermittent (partial torsion with spontaneous resolution and recurrence).

Cyst Rupture

Spontaneous or traumatic rupture (post-coital, post-exercise) results in intraperitoneal spillage. Simple cyst rupture typically produces transient pelvic pain that resolves within hours. Hemorrhagic corpus luteum rupture may cause hemoperitoneum with peritoneal signs, hypotension, and significant blood loss requiring surgical intervention, particularly in women on anticoagulants.

Features Suggesting Malignancy

Post-menopausal presentation, bilateral lesions, rapid growth, solid or complex ultrasound morphology, ascites, and elevated CA-125 are features warranting urgent specialist assessment. Paraneoplastic syndromes (hypercalcemia from small cell carcinoma; androgenic excess from Sertoli-Leydig cell tumors causing virilization) may present as systemic rather than pelvic symptoms.

6. Diagnosis

Transvaginal Ultrasound (TVUS)

The primary imaging modality for ovarian cyst assessment. Key descriptors include: cyst size (maximum diameter in three planes), morphology (unilocular, multilocular, solid, mixed), wall characteristics (thin/regular vs. irregular/thick), internal echogenicity (anechoic, ground-glass, mixed, hyperechoic), presence and characteristics of papillary projections or solid components, septation (number, thickness), and Doppler flow within solid components or septa.

IOTA Simple Rules

Validated ultrasound classification system using five benign features (B-rules) and five malignant features (M-rules):

Benign (B) features:

Malignant (M) features:

If only B features are present: classify as benign (sensitivity 95%, specificity 74%). If only M features: classify as malignant (sensitivity 92%, specificity 96%). If both or neither: inconclusive — apply further assessment (ADNEX model, MRI, specialist referral).

IOTA ADNEX Model

A multivariate logistic regression model incorporating five ultrasound variables (maximum lesion diameter, proportion of solid tissue, number of papillary projections, more than 10 locules, acoustic shadows) and two clinical variables (patient age, CA-125, and clinical setting — oncology center vs. non-oncology). Outputs continuous probability estimates for five diagnostic categories: benign, borderline, stage I invasive, stage II–IV invasive, and secondary metastatic. An ADNEX risk above 10% for malignancy is generally used as a threshold for specialist referral.

O-RADS Ultrasound Classification

The ACR O-RADS ultrasound lexicon assigns risk categories:

O-RADS MRI

MRI is the second-line modality for indeterminate lesions on ultrasound (O-RADS 3–4 or inconclusive IOTA Simple Rules). MRI O-RADS assigns categories 1–5 based on T1/T2 signal characteristics, enhancement patterns, restricted diffusion, and associated findings. Key MRI features: T1 hyperintensity (dermoid fat, endometrioma blood products), T2 "shading" (endometrioma), T2 hypointensity of fibrous solid components (fibroma, Brenner tumor), restricted diffusion in malignant solid components (ADC below 0.9 × 10⁻³ mm²/s), and early arterial enhancement.

Serum Biomarkers

Additional Investigations

7. Treatment

Expectant Management — Functional Cysts

Simple unilocular cysts under 5 cm in pre-menopausal women (O-RADS 2) require no intervention — approximately 70% resolve spontaneously within 2–3 cycles. Reassurance and repeat TVUS in 6–12 weeks is appropriate. The role of oral contraceptives to promote cyst regression has not been supported in randomized trials and is not routinely recommended for established cysts; however, OCP use does reduce new functional cyst formation.

RCOG (Royal College of Obstetricians and Gynaecologists) guidelines recommend observation without surgery for simple unilocular ovarian cysts under 5 cm in both pre- and post-menopausal women, with annual ultrasound follow-up. ACOG (American College of Obstetricians and Gynecologists) and SRU (Society of Radiologists in Ultrasound) provide size-stratified follow-up intervals based on O-RADS category and menopausal status.

Management by Cyst Type

Endometrioma

Expectant management is appropriate for small endometriomas (under 3–4 cm) in asymptomatic women not planning IVF. Surgical management (laparoscopic cystectomy — stripping technique) is recommended for: symptomatic endometriomas causing intractable pain or dyspareunia, endometriomas above 4 cm in women planning IVF (to reduce contamination risk during oocyte retrieval and improve follicular access), and when malignancy cannot be excluded. The stripping technique (Bruhat method) — developing the cleavage plane between the cyst wall and ovarian cortex — is superior to fenestration/coagulation in reducing recurrence rates. However, follicle-containing ovarian cortex is inevitably removed, permanently reducing ovarian reserve (AMH decrease of 30–40% per operated ovary). Medical therapy (continuous OCP, progestins, GnRH agonists with add-back, dienogest) is used for symptom control and recurrence prevention but does not eliminate endometriomas.

Dermoid Cyst (Mature Cystic Teratoma)

Surgical removal is indicated for dermoids above 5–6 cm due to torsion risk, symptomatic lesions, and diagnostic uncertainty. Laparoscopic cystectomy with spillage prevention is the preferred approach — copious irrigation is mandatory if spillage occurs to prevent chemical peritonitis from sebaceous material. Oophorectomy is indicated for very large dermoids occupying the entire ovary, suspected malignant transformation (solid component, rapid growth in post-menopausal women), or surgical inaccessibility of the normal ovarian parenchyma. Bilateral involvement occurs in 10–15% of cases; careful inspection of the contralateral ovary is mandatory.

Cystadenoma

Serous and mucinous cystadenomas require laparoscopic or open cystectomy or oophorectomy depending on lesion size, patient age, and desire for fertility preservation. Spillage of mucinous contents should be minimized to reduce pseudomyxoma peritonei risk (though primary ovarian mucinous carcinoma with pseudomyxoma is far less common than appendiceal primary). Frozen section analysis is recommended intraoperatively for large or complex lesions to guide extent of surgery. Borderline tumors (low malignant potential) typically require only salpingo-oophorectomy with comprehensive surgical staging in post-menopausal women; fertility-preserving cystectomy may be considered in young women with stage I borderline tumors after thorough counseling.

Ovarian Torsion — Surgical Emergency

Torsion requires urgent surgical intervention, ideally within 6–8 hours of symptom onset to maximize ovarian salvage. Laparoscopic detorsion (untwisting the pedicle) is the preferred approach regardless of ovarian appearance — even a necrotic-appearing ovary should be detorsed before oophorectomy decision, as studies demonstrate that up to 93% of clinically black/necrotic ovaries recover function after detorsion. The ovary should be reassessed laparoscopically 24–48 hours post-detorsion via a second-look procedure if viability remains questionable. Concurrent cystectomy at the time of detorsion is controversial — cystectomy may be performed if the cyst is clearly benign (dermoid, simple cyst), but delayed elective cystectomy 6–8 weeks post-detorsion is preferred to minimize the risk of reoperation in an acutely inflamed pelvis. Oophoropexy (shortening the utero-ovarian ligament or fixing the ovary to the posterior leaf of the broad ligament) is recommended to prevent recurrent torsion, particularly in young women after detorsion and in the contralateral ovary in cases of congenitally long utero-ovarian ligament.

Hemorrhagic Cyst Rupture

Management depends on hemodynamic stability. Hemodynamically stable patients with small-to-moderate hemoperitoneum (identified on ultrasound or CT) and resolving pain are managed conservatively with close observation, analgesia, CBC monitoring, and serial abdominal examination. Hemodynamically unstable patients or those with refractory pain and significant hemoperitoneum require laparoscopic surgical exploration with hemostasis (electrocautery, suture, topical hemostatic agents) and evacuation of hemoperitoneum. Blood transfusion as required. Women on anticoagulation are at highest risk and require low threshold for surgical intervention.

Suspected Ovarian Malignancy — Specialist Referral

Women with O-RADS 4–5 lesions, ADNEX malignancy probability above 10–15%, or elevated CA-125 and post-menopausal status should be referred to a gynecologic oncologist. Comprehensive surgical staging (peritoneal washings, total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and para-aortic lymph node sampling, biopsy of any suspicious lesions) is the standard for suspected invasive ovarian carcinoma. Fertility-preserving staging (unilateral salpingo-oophorectomy) may be considered for apparent stage IA disease in young women after thorough staging and counseling.

8. Complications

9. Prognosis

The prognosis of ovarian cysts is overwhelmingly favorable for functional and benign neoplastic lesions. Simple functional cysts resolve in 70–80% of pre-menopausal women within 2–3 cycles without intervention. Endometriomas recur in approximately 30–50% within 5 years of cystectomy; recurrence rates are reduced by post-operative hormonal suppression (dienogest, OCP). Dermoid cysts do not recur after complete excision; bilateral tumors are present in 10–15% and require vigilant follow-up of the contralateral ovary.

Ovarian torsion with prompt detorsion within 6–8 hours preserves ovarian function in approximately 90–95% of cases. When ovarian ischemia is prolonged (greater than 36 hours), oophorectomy is frequently required, with permanent loss of ovarian function on the affected side.

Ovarian cancer prognosis is stage-dependent: 5-year survival for stage I disease is approximately 90%; stage II 70%; stage III 25–45%; stage IV 5–20%. The poor overall prognosis for ovarian cancer (combined 5-year survival approximately 47%) reflects the predominance of advanced-stage diagnoses due to late symptom onset and lack of effective screening.

10. Prevention

11. Recent Research

12. References

  1. Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839. doi:10.1136/bmj.c6839
  2. Van Calster B, Valentin L, Savelli L, et al. Triaging women with ovarian masses for surgery: observational diagnostic study to compare IOTA ADNEX model, RMI and CA125. BJOG. 2017;124(1):132–141. doi:10.1111/1471-0528.13762
  3. Andreotti RF, Timmerman D, Strachowski LM, et al. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology. 2020;294(1):168–185. doi:10.1148/radiol.2019191150
  4. Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, et al. Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses. JAMA Netw Open. 2020;3(1):e1919896. doi:10.1001/jamanetworkopen.2019.19896
  5. Guerriero S, Condous G, van den Bosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016;48(3):318–332. doi:10.1002/uog.15955
  6. RCOG. Management of Suspected Ovarian Masses in Premenopausal Women. Green-top Guideline No. 62. Royal College of Obstetricians and Gynaecologists; 2011 (revised 2016). Available at: rcog.org.uk
  7. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016;128(5):e210–e226. doi:10.1097/AOG.0000000000001768
  8. Somigliana E, Berlanda N, Benaglia L, et al. Surgical excision of endometriomas versus ovarian cystectomy with reconsideration of the ovarian reserve. Fertil Steril. 2012;98(6):1531–1537. doi:10.1016/j.fertnstert.2012.08.023
  9. Muzii L, Di Tucci C, Di Feliciantonio M, et al. The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. Hum Reprod. 2014;29(10):2190–2198. doi:10.1093/humrep/deu199
  10. Pereira N, Petrini AC, Lekovich JP, Elias RT, Spandorfer SD. Surgical management of endometrioma prior to in vitro fertilization: a systematic review. J Endometr Pelvic Pain Disord. 2016;8(2):53–60. doi:10.5301/je.5000217
  11. McGrath S, Reid F. Ovarian torsion: evidence base for current and future surgical management. Best Pract Res Clin Obstet Gynaecol. 2021;74:25–36. doi:10.1016/j.bpobgyn.2021.02.007
  12. Oelsner G, Shashar D. Adnexal torsion. Clin Obstet Gynecol. 2006;49(3):459–463. doi:10.1097/00003081-200609000-00006
  13. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008;90(5):1559–1570. doi:10.1016/j.fertnstert.2008.08.007
  14. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. doi:10.1093/annonc/mdz062
  15. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101(2):80–87. doi:10.1093/jnci/djn442
  16. Kho RM, Magrina JF, Magtibay PM. Pathologic findings and outcomes of a minimally invasive approach to ovarian dermoid cyst. Fertil Steril. 2007;87(5):1210–1213. doi:10.1016/j.fertnstert.2006.10.013
  17. Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017;9:115–130. doi:10.2147/CMAR.S113874
  18. Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14(3):5367–5379. doi:10.3390/ijms14035367

Back to Table of Contents